Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open label prospective study of Sofosbuvir, Velpatasvir, voxilaprevir assessing efficacy and safety in the treatment of triple infection with Chronic Hepatitis C, Chronic Hepatitis B, and HIV

Trial Profile

An Open label prospective study of Sofosbuvir, Velpatasvir, voxilaprevir assessing efficacy and safety in the treatment of triple infection with Chronic Hepatitis C, Chronic Hepatitis B, and HIV

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Nov 2018

At a glance

  • Drugs Sofosbuvir/velpatasvir/voxilaprevir (Primary)
  • Indications Hepatitis B; Hepatitis C; HIV infections
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms SOLVVE-C
  • Most Recent Events

    • 13 Nov 2018 New trial profile.
    • 13 Nov 2018 Results presented at The Liver Meeting 2018: 69th Annual Meeting of the American Association for the Study of Liver Diseases
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top